Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

43.560
-0.400-0.91%
Volume:1.38M
Turnover:59.89M
Market Cap:289.11B
PE:31.60
High:43.900
Open:43.900
Low:43.200
Close:43.960
52wk High:94.869
52wk Low:43.200
Shares:6.64B
HK Float Shares:258.00M
Volume Ratio:1.03
T/O Rate:0.53%
Dividend:0.23
Dividend Rate:0.54%
EPS(LYR):1.379
ROE:12.46%
ROA:7.02%
PB:3.84
PE(LYR):31.60
PS:7.90

Loading ...

Hengrui Pharma Shares Surge Over 6% on New Drug Indication Approval and International Expansion Success

Stock News
·
Jul 02

Movement Alert|Hengrui Pharma Rises 3.72% in Regular Trading, Pharmaceutical Sector Rally and Multiple Drug Approvals Drive Gains

Market Focus
·
Jul 02

AH Share Premium and Deviation Rankings as of July 1st Close

Stock News
·
Jul 01

AH Share Premium and Deviation Rankings as of June 30th Close

Stock News
·
Jun 30

AH Share Premium and Deviation Data for June 29th

Stock News
·
Jun 29

Movement Alert|Hengrui Pharma Rises 3.02% in Regular Trading, Pharma Sector Rallies as Multiple Regulatory Milestones Boost Sentiment

Market Focus
·
Jun 29

AH Share Premium and Deviation Rankings for June 26

Stock News
·
Jun 26

Hengrui Pharma Gets Nod to Trial HRS-4508 Tablets As Advanced Tumor Treatment; Shares Down 4%

MT Newswires Live
·
Jun 26

Hengrui Pharmaceuticals Unit Wins China Approval to Expand Indication of Cancer Drug

MT Newswires Live
·
Jun 26

Movement Alert|Hengrui Pharmaceuticals Falls 3.53% in Regular Trading, Trading at 54.15 HKD

Market Focus
·
Jun 26

Hengrui Pharmaceuticals Unit Wins China Marketing Approval for Dry Eye Drug

MT Newswires Live
·
Jun 26

Hengrui Pharma Secures NMPA Approval for Adebrelimab as China’s First Domestic Peri-operative PD-L1 Therapy for Resectable NSCLC

Bulletin Express
·
Jun 25

Hengrui Pharma secures NMPA green light for China’s first 0.1% water-free cyclosporine eye-drop

Bulletin Express
·
Jun 25

Hengrui Pharma's Adebrelimab Injection Gains Approval for Additional NSCLC Perioperative Indication

Stock News
·
Jun 25

Jiangsu Hengrui Pharmaceuticals - Subsidiary Received Notification from Nmpa Approving New Indication for Adebrelimab Injection

THOMSON REUTERS
·
Jun 25

AH Share Premium and Deviation Rankings as of June 24th Close

Stock News
·
Jun 24

Movement Alert|Hengrui Medicine Rises 3.47% in Regular Trading, First Self-Developed Innovative Drug Marketing Application Accepted by EMA

Market Focus
·
Jun 24

Hengrui Pharma Withdraws Registration Application for Emaxitinib Ointment

Stock News
·
Jun 23

Hong Kong Stocks Surge: Innovative Drug Sector Rallies on Regulatory Report and New Foreign Investment Policies

Stock News
·
Jun 23

European Drug Regulator Accepts Hengrui Pharma's Marketing Application for Revulutamide Tablets

MT Newswires Live
·
Jun 23